8/3/2023 0 Comments Illuminate cars![]() ![]() BCMA is the target toward which all CAR T cells are directed. The Fred presented a CAR product that includes which is an upregulator for BCMA. In the relapsed/refractory multiple myeloma space, we have too many patients and very few slots.Ĭould you highlight any other intriguing ongoing trials and further research that are investigating CAR T-cell therapies within multiple myeloma? It is incumbent upon us as to how we can make them accessible, because on average, we’re able to take care of 1 or 2 patients with each of these drug products. For example, you need to consider whether you have enough viral vector, and if you don’t, you’re not going to be able to create the CAR. It’s not easy to get slots there are many bottlenecks involved in the production of CAR T cells. The struggle is that these therapies are not treatments that are off-the-shelf and readily available to our patients, especially given that we are trying to do personalized, designer-specific therapy for each patient. The good news is that these approvals are going to allow us access to. How can these new CAR T-cell therapies help evolve the treatment landscape for multiple myeloma? The goal is to enrich for a memory naïve-like phenotype, with the intent of having a longer duration of response. The idea with that product is to expose the CAR product ex vivo so that in vitro, you’re exposing it to a drug product called bb007, which is a PI3 kinase inhibitor. We want to know: Can we do better than that? That was the presentation I gave on bb21217. We know that ide-cel produces a complete response rate of close to 40%, which translates into a of about 22 months. What we’re trying to do with all these strategies, many of which were presented at ASH, is find ways to improve upon what we already have with CAR T cells. I talked about data with the CAR product bb21217, which is similar to ide-cel. Most of these patients a CD38 monoclonal antibody. with relapsed/refractory multiple myeloma who have previously been exposed to many other drugs, including both immunomodulatory drugs, lenalidomide and pomalidomide, bortezomib, and carfilzomib. ![]() We have ide-cel, which was approved in March 2021, and more recently, we have cilta-cel, which was approved in March 2022. We now have 2 CAR T-cell therapy products approved. Raje: CAR T cells are an exciting development in the treatment of patients with multiple myeloma. Could you provide a brief overview of some of the topics you talked about? OncLive ®: The presentation you gave at ASH focused on the role of CAR T cells in multiple myeloma. In an interview with OncLive ®, Raje discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility. “There is much excitement around CAR T cells ide-cel and cilta-cel are our first foray into the CAR T-cell world,” Raje, director of the Center for Multiple Myeloma at Massachusetts General Hospital, said. Raje, MD, who also spoke about augmenting the landscape with off-the-shelf options such as BCMA-directed bispecific T-cell engagers (BiTEs). The FDA approvals of idecabtagene vicleucel (ide-cel Abecma) and ciltacabtagene autoleucel (cilta-cel Carvykti) are shifting the treatment paradigm for patients with relapsed/refractory multiple myeloma, according to Noopur S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |